Complex treatment of non-alcoholic fatty liver disease: experience of the use of hepatoprotectors
Journal Title: Сучасна гастроентерологія - Year 2018, Vol 0, Issue 2
Abstract
Objective — to evaluate the complex therapy effects at the levels of cytokeratin (CK)-18, fibroblast growth factor (FGF)-21 and metabolic parameters of nonalcoholic fatty liver disease (NAFLD) patients. Materials and methods. examinations involved 90 patients with NAFLD, aged 30 to 60 years (the men age (48.61 ± 4.1) years). The control group consisted of 20 practically healthy volunteers. Gender difference between groups wasn’t significant. Levels of SC-18 and FGF-21 with the use immune enzyme method with ELISA kits were performed at baseline and 1 months after the beginning of treatment with combination of ursodeoxycholic acid and ademetionine, Results. Before the treatment, NAFLD patients demonstrated the increased liver enzymatic activity (р ≤ 0.05); lipid profile indices (p ≤ 0.05); the increased levels of insulin and HOMAIR (p = 0.002), and plasma levels of cytokines CK-18 and FGF-21 (p ≤ 0.05). After 1 months of treatment, the following positive effects were revealed: reduction of ALT and AST levels (p ≤ 0.05), decrease of glucose levels by 10.5 %, HOMA index by 41 % (p = 0.001), level of total cholesterol decreased from 5.6 to 4.89 mmol/L, triglycerides’ levels from 1.7 to 1.24 mmol/L (p = 0.001). Conclusions. The combined therapy of ademetionine and ursodeoxycholic acid in patients with NAFLD promoted the reduction of the transaminases’, glucose levels and HOMAindex, resulted in the eliminating of hyperlipidemia and hypertriglyceridemia, as well as reducing of apoptotic processes in the liver.
Authors and Affiliations
O. Ya. Babak, K. A. Lapshyna, А. M. Chernyak
Keywords
Related Articles
- EP ID EP295148
- DOI -
- Views 122
- Downloads 0
Non-invasive diagnosis of non-alcoholic fatty liver disease: the available opportunities we have today
Non-alcoholic fatty liver disease (NAFLD) is becoming an increasingly common disease, it is currently diagnosed in more than a quarter of adult population worldwide, and its portion in the overweight patients with type 2...
The role of serum biomarkers in the diagnosis of nonalcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by liver steatosis and the ability to progress to more serious pathological conditions, including non-alcoholic steatohepatitis (NASH), fibrosis and ci...
Peculiarities of the clinical course and visceral adipose tissue in patients with non-alcoholic fatty liver disease against the background of metabolic syndrome
Objective — to study the peculiarities of metabolic disturbances in patients with nonalcoholic fatty liver disease (NAFLD) and their role in the development and progression of liver steatosis. Materials and methods. Inv...
Autoimmune gastritis: problems of diagnosis and therapy
Chronic gastritis (CG) is one of the most widespread internal diseases, which affects up to 20 % of the adult population. The modern CG paradigm considers disease as a launchpad for the formation of stomach cancer, as we...
Effects of L-ornithine-L-aspartate on the manifestation of minimal hepatic encephalopathy in the dynamics of cytostatic therapy
Objective — to investigate effects of the L-ornithine-L-aspartate (LOLA, Hepa-Merz®) on the clinical manifestations of minimal hepatic encephalopathy (HE) in patients with multiple myeloma (MM) in the dynamics of cytosta...